DD264924A5 - Verfahren zur herstellung von pyrimidin-nucleosiden - Google Patents

Verfahren zur herstellung von pyrimidin-nucleosiden Download PDF

Info

Publication number
DD264924A5
DD264924A5 DD87310427A DD31042787A DD264924A5 DD 264924 A5 DD264924 A5 DD 264924A5 DD 87310427 A DD87310427 A DD 87310427A DD 31042787 A DD31042787 A DD 31042787A DD 264924 A5 DD264924 A5 DD 264924A5
Authority
DD
German Democratic Republic
Prior art keywords
group
compound
hydrogen
formula
hydroxy
Prior art date
Application number
DD87310427A
Other languages
German (de)
English (en)
Inventor
Saad G Rahim
Dorothy J M Purifoy
Original Assignee
��������@��������@����������@���k��
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ��������@��������@����������@���k�� filed Critical ��������@��������@����������@���k��
Publication of DD264924A5 publication Critical patent/DD264924A5/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Silicon Polymers (AREA)
  • Developing Agents For Electrophotography (AREA)
  • Apparatus For Radiation Diagnosis (AREA)
DD87310427A 1986-12-15 1987-12-14 Verfahren zur herstellung von pyrimidin-nucleosiden DD264924A5 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB868629892A GB8629892D0 (en) 1986-12-15 1986-12-15 Antiviral compounds

Publications (1)

Publication Number Publication Date
DD264924A5 true DD264924A5 (de) 1989-02-15

Family

ID=10609013

Family Applications (2)

Application Number Title Priority Date Filing Date
DD87310427A DD264924A5 (de) 1986-12-15 1987-12-14 Verfahren zur herstellung von pyrimidin-nucleosiden
DD87320503A DD274766A5 (de) 1986-12-15 1987-12-14 Verfahren zur herstellung einer pharmazeutischen formulierung

Family Applications After (1)

Application Number Title Priority Date Filing Date
DD87320503A DD274766A5 (de) 1986-12-15 1987-12-14 Verfahren zur herstellung einer pharmazeutischen formulierung

Country Status (30)

Country Link
US (1) US5079235A (cs)
EP (3) EP0272065B1 (cs)
JP (2) JPS63165397A (cs)
KR (1) KR880007521A (cs)
CN (2) CN87108265A (cs)
AT (1) ATE88713T1 (cs)
AU (2) AU601529B2 (cs)
CA (1) CA1319143C (cs)
CS (3) CS275398B2 (cs)
DD (2) DD264924A5 (cs)
DE (1) DE3785651T2 (cs)
DK (2) DK654287A (cs)
ES (1) ES2054693T3 (cs)
FI (2) FI875487A7 (cs)
GB (1) GB8629892D0 (cs)
HU (4) HU202112B (cs)
IE (2) IE930471L (cs)
IL (3) IL95141A (cs)
LT (1) LT2064B (cs)
LV (1) LV5273A3 (cs)
MC (1) MC1882A1 (cs)
MX (1) MX9203216A (cs)
NO (1) NO167576C (cs)
NZ (1) NZ222898A (cs)
PH (2) PH24104A (cs)
PL (3) PL158050B1 (cs)
PT (1) PT86356B (cs)
RU (1) RU2036199C1 (cs)
SU (1) SU1731064A3 (cs)
ZA (1) ZA879382B (cs)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2828642B2 (ja) * 1987-06-24 1998-11-25 ハワード フローレイ インスティテュト オブ イクスペリメンタル フィジオロジー アンド メディシン ヌクレオシド誘導体
US4954485A (en) * 1987-10-20 1990-09-04 Sanyo-Kokusaku Pulp Co., Ltd. 2',3'-dideoxy-4-thio-uridine derivatives, process for their preparation and antivirus agents using them
EP0346108A3 (en) * 1988-06-09 1991-04-24 The Wellcome Foundation Limited Anti-infective nucleosides
US5157114A (en) * 1988-08-19 1992-10-20 Burroughs Wellcome Co. 2',3'-dideoxy-3'-fluoro-5-ethyngluridine
GB8827339D0 (en) * 1988-11-23 1988-12-29 Wellcome Found Antiviral compounds
US5006646A (en) * 1989-02-22 1991-04-09 Yuki Gosei Kogyo Co., Ltd. Process for preparing 2'-deoxy-5-trifluoromethyl-beta-uridine
IE902574A1 (en) * 1989-07-17 1991-02-27 Univ Birmingham Antiviral pyrimidine nucleosides
DD293498A5 (de) * 1989-07-20 1991-09-05 Zi Fuer Molekularbiologie Der Adw,De Verfahren zur herstellung eines mittels fuer die behandlung oder prophylaxe von hepatits-infektionen bei mensch und tier
GB8919607D0 (en) * 1989-08-30 1989-10-11 Wellcome Found Novel entities for cancer therapy
US6337209B1 (en) 1992-02-26 2002-01-08 Glaxo Wellcome Inc. Molecular constructs containing a carcinoembryonic antigen regulatory sequence
GB9008696D0 (en) * 1990-04-18 1990-06-13 Wellcome Found Anti-viral compounds
GB9012899D0 (en) * 1990-06-09 1990-08-01 Wellcome Found Anti-hbv pyrimidine nucleoside
GB9014618D0 (en) * 1990-06-30 1990-08-22 Wellcome Found Process for the preparation of pyrimidine nucleosides
US5643913A (en) * 1990-07-19 1997-07-01 Glaxo Wellcome Inc. Pharmaceutical compositions of 5-substituted uracil compounds
EP0711555A2 (en) * 1990-07-19 1996-05-15 The Wellcome Foundation Limited Enzyme inactivators
GB9020930D0 (en) 1990-09-26 1990-11-07 Wellcome Found Pharmaceutical combinations
GB9104165D0 (en) * 1991-02-27 1991-04-17 Wellcome Found Novel entities for hiv therapy
GB9111580D0 (en) * 1991-05-30 1991-07-24 Wellcome Found Nucleoside derivative
US5646123A (en) * 1991-06-10 1997-07-08 Alberta Research Council Time dependent administration of oligosaccharide glycosides related to blood group determinants having a type I or type II core structure in reducing inflammation in a sensitized mammal arising form exposure to an antigen
US5580858A (en) * 1991-06-10 1996-12-03 Alberta Research Council Immunosuppressive and tolerogenic modified Lewisx compounds
HU207524B (en) * 1991-11-22 1993-04-28 Mta Koezponti Kemiai Kutato In Industrial process for producing 5-alkyl-2'-deoxy-beta-uridines with stereoselective synthesis
US6235887B1 (en) 1991-11-26 2001-05-22 Isis Pharmaceuticals, Inc. Enhanced triple-helix and double-helix formation directed by oligonucleotides containing modified pyrimidines
US5484908A (en) * 1991-11-26 1996-01-16 Gilead Sciences, Inc. Oligonucleotides containing 5-propynyl pyrimidines
ATE226093T1 (de) * 1991-11-26 2002-11-15 Isis Pharmaceuticals Inc Gesteigerte bildung von triple- und doppelhelices aus oligomeren mit modifizierten pyrimidinen
TW393513B (en) * 1991-11-26 2000-06-11 Isis Pharmaceuticals Inc Enhanced triple-helix and double-helix formation with oligomers containing modified pyrimidines
CA2118405A1 (en) * 1992-05-26 1993-09-12 Robert Maurice Ippolito Immunosuppressive and tolerogenic modified lewisc and lacnac compounds
CA2119315A1 (en) * 1993-03-18 1994-09-19 Tsujiaki Hata Nucleoside derivatives and anti-herpes composition
US6432924B1 (en) 1993-12-26 2002-08-13 East Carolina University Method of treating disorders characterized by overexpression of cytidine deaminase or deoxycytidine deaminase
WO1996018636A1 (fr) * 1994-12-13 1996-06-20 Taiho Pharmaceutical Co., Ltd. Derives de nucleoside substitues en 3'
US6136791A (en) * 1995-12-22 2000-10-24 East Carolina University Agent and method for treating disorders associated with cytidine deaminase or deoxycytidine deaminase overexpression
WO1997027849A1 (fr) * 1996-02-02 1997-08-07 Showa Shell Sekiyu K.K. Medicaments pour traiter les infections provoquees par le virus de l'herpes et compositions preventives pour empecher un retour de l'infection, contenant tous les deux des derives triterpeniques comme principe actif
RU2300381C2 (ru) * 1998-08-10 2007-06-10 Айденикс (Кайман) Лимитед β-L-2'-ДЕЗОКСИНУКЛЕОЗИДЫ ДЛЯ ЛЕЧЕНИЯ ГЕПАТИТА В
US6653318B1 (en) * 1999-07-21 2003-11-25 Yale University 5-(E)-Bromovinyl uracil analogues and related pyrimidine nucleosides as anti-viral agents and methods of use
US7019129B1 (en) 2000-05-09 2006-03-28 Biosearch Technologies, Inc. Dark quenchers for donor-acceptor energy transfer
WO2003053360A2 (en) * 2001-12-20 2003-07-03 Pharmassett Ltd. Treatment of ebv and khsv infection and associated abnormal cellular proliferation
CN102441170A (zh) 2004-12-03 2012-05-09 阿迪赫里克斯技术公司 与5-fu和5-fu前药组合施用dpd抑制剂的方法
PT2757091T (pt) 2008-04-01 2017-07-24 Biosearch Tech Inc Sondas de fluoróforo e supressor de fluorescência de ácido nucleico estabilizadas
CN101768197A (zh) * 2008-12-29 2010-07-07 北京德众万全药物技术开发有限公司 一种奈拉滨的制备方法
JP2013508293A (ja) 2009-10-14 2013-03-07 アドヘレックス テクノロジーズ， インコーポレイテッド ５−ｆｕ又はそのプロドラッグと、ｄｐｄ阻害剤との組合せに付随した神経毒性の処置
JP6574240B2 (ja) * 2014-03-30 2019-09-11 セフィエド 修飾シトシンポリヌクレオチドオリゴマーおよび方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1601020A (en) * 1978-04-24 1981-10-21 Stichting Grega Vzw 2'-deoxy-5 (2-halogenovinyl)-uridines
US4211773A (en) * 1978-10-02 1980-07-08 Sloan Kettering Institute For Cancer Research 5-Substituted 1-(2'-Deoxy-2'-substituted-β-D-arabinofuranosyl)pyrimidine nucleosides
US4247544A (en) * 1979-07-02 1981-01-27 The Regents Of The University Of California C-5 Substituted uracil nucleosides
US4267171A (en) * 1979-07-02 1981-05-12 The Regents Of The University Of California C-5 Substituted cytosine nucleosides
US4274544A (en) * 1980-03-11 1981-06-23 The Continental Group, Inc. Single-piece plastic closure having integral seal forming means
EP0082667A1 (en) * 1981-12-18 1983-06-29 Beecham Group Plc Pharmaceutical compositions
EP0082668A1 (en) * 1981-12-18 1983-06-29 Beecham Group Plc 5-(2-Halogenovinyl)-2'-deoxyuridine derivatives, processes for their preparation, pharmaceutical compositions containing them and their use in treating viral infections
EP0095294A1 (en) * 1982-05-22 1983-11-30 Beecham Group Plc Deoxyuridine compounds, methods for preparing them and their use in medicine
EP0097039A1 (en) * 1982-06-16 1983-12-28 Beecham Group Plc 5-(E-2-halovinyl)-2'-deoxyuridine derivatives, processes for their preparation, pharmaceutical compositions containing them, and their use in treating viral infections
GB8517402D0 (en) * 1985-07-10 1985-08-14 Wellcome Found Treatment of viral infections
DE3650741T2 (de) * 1985-09-17 2000-10-12 The Wellcome Foundation Ltd., Greenford Kombination therapeutische Nukleoside mit weiteren therapeutisch wirksamen Komponenten.
SE8701605D0 (sv) * 1987-04-16 1987-04-16 Astra Ab Novel medicinal compounds

Also Published As

Publication number Publication date
FI875487A7 (fi) 1988-06-16
CS767588A3 (en) 1991-02-12
JPH0378370B2 (cs) 1991-12-13
PL160321B1 (pl) 1993-02-26
DK654287A (da) 1988-06-16
IL84810A (en) 1992-05-25
ATE88713T1 (de) 1993-05-15
IE930470L (en) 1988-06-15
DK169991A (da) 1991-10-04
DE3785651T2 (de) 1993-11-11
IL84810A0 (en) 1988-06-30
IE930471L (en) 1988-06-15
PH24870A (en) 1990-12-26
JPH03141292A (ja) 1991-06-17
NO875209L (no) 1988-06-16
MX9203216A (es) 1992-07-01
JPS63165397A (ja) 1988-07-08
NO875209D0 (no) 1987-12-14
AU601529B2 (en) 1990-09-13
NO167576B (no) 1991-08-12
EP0417560A1 (en) 1991-03-20
KR880007521A (ko) 1988-08-27
CA1319143C (en) 1993-06-15
SU1731064A3 (ru) 1992-04-30
ZA879382B (en) 1989-08-30
FI941523L (fi) 1994-03-31
EP0272065A3 (en) 1988-11-17
AU5989090A (en) 1990-11-08
CN1080292A (zh) 1994-01-05
NO167576C (no) 1991-11-20
PT86356A (en) 1988-01-01
PH24104A (en) 1990-03-05
PL277926A1 (en) 1989-08-21
GB8629892D0 (en) 1987-01-28
US5079235A (en) 1992-01-07
EP0272065B1 (en) 1993-04-28
EP0486477A3 (en) 1992-06-17
NZ222898A (en) 1990-12-21
FI941523A0 (fi) 1994-03-31
EP0486477A2 (en) 1992-05-20
EP0272065A2 (en) 1988-06-22
MC1882A1 (fr) 1989-01-24
LT2064B (lt) 1993-06-15
IL95141A (en) 1992-05-25
DK168323B1 (da) 1994-03-14
HU207735B (en) 1993-05-28
ES2054693T3 (es) 1994-08-16
PT86356B (pt) 1990-11-07
PL269462A1 (en) 1989-06-26
FI875487A0 (fi) 1987-12-14
RU2036199C1 (ru) 1995-05-27
DK169991D0 (da) 1991-10-04
DK654287D0 (da) 1987-12-14
CS275398B2 (en) 1992-02-19
AU8252187A (en) 1988-06-16
LV5273A3 (lv) 1993-10-10
PL160322B1 (pl) 1993-02-26
DD274766A5 (de) 1990-01-03
CS342591A3 (en) 1992-04-15
AU626041B2 (en) 1992-07-23
CS916187A2 (en) 1991-02-12
HU903829D0 (en) 1990-11-28
HU202112B (en) 1991-02-28
DE3785651D1 (de) 1993-06-03
FI941523A7 (fi) 1994-03-31
CS275402B6 (en) 1992-02-19
PL158050B1 (pl) 1992-07-31
IL95141A0 (en) 1991-06-10
HUT46336A (en) 1988-10-28
HU200932B (en) 1990-09-28
CN87108265A (zh) 1988-07-13
HU199867B (en) 1990-03-28
PL277927A1 (en) 1989-08-21

Similar Documents

Publication Publication Date Title
DD264924A5 (de) Verfahren zur herstellung von pyrimidin-nucleosiden
DE69025529T2 (de) Weitere antivirale Pyrimidin-Nukleosiden
DE3855522T2 (de) Antivirale Verbindungen
DE68922903T2 (de) Antivirale Pyrimidin- und Purinverbindungen, Verfahren zu ihrer Herstellung und sie enthaltende pharmazeutische Präparate.
DD282229A5 (de) Verfahren zur herstellung von therapeutischen acyclischen nucleosiden
DE69116750T2 (de) 9-Purinyl-Phosphonsäurederivate
DE3855333T2 (de) Therapeutische Nukleoside
DE3650492T2 (de) Therapeutische Nukleoside
DD202717A5 (de) Antivirale purinderivate und verfahren zu ihrer herstellung
CH629805A5 (de) Verfahren zur herstellung neuer substituierter purine.
DE3876174T2 (de) 2',3'-dideoxy-3'-fluorothymidin und verwandte verbindungen zur behandlung von adenovirus-infektionen.
EP0023594B1 (de) Trans-Chinazolinderivate, Verfahren zu ihrer Herstellung, Zwischenprodukte und Arzneimittel enthaltend solche Chinazolinderivate
DD261095A5 (de) Verfahren zur herstellung von antiviralen kombinationen
DE69527294T2 (de) 4-[2-amino-6-(cyclopropylamino)-9h-pyrin-9-yl]-2-cyclopenten-1-methanol-succinat als antivirales mittel
CH676712A5 (cs)
DE69132052T2 (de) Uracil-reductase-inaktivator
DE3228060A1 (de) Verfahren zum behandeln von wuchernden hautkrankheiten
DE69412073T2 (de) Xanthinderivate als adenosin-a1 rezeptor antagonisten
DE69128626T2 (de) Enzyminaktivatoren
DE68926697T2 (de) Ester von 9-(2-Hydroxyethoxymethyl)guanin
DE3872028T2 (de) Therapeutische nucleoside.
DE68914809T2 (de) Antivirale Wirkstoffe.
DD251984A5 (de) Verfahren zur herstellung von 3'-azidonucleosiden und pharmazeutisch vertraeglichen derivaten davon
DD287406A5 (de) Therapeutische nucleoside
US5028596A (en) 1-(β-D-arabinofuranosyl)-5-propynyluracil for treatment of VZV infections

Legal Events

Date Code Title Description
ENJ Ceased due to non-payment of renewal fee